loader

Surrozen Inc.

NASDAQ:SRZN
1 min read

Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver in Milan

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology Annual Meeting

Surrozen Provides First Quarter 2024 Financial Results and Business Update

Surrozen Inc is a class of therapeutics to treat serious diseases characterized by tissue injury. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), and SZN-043 (E3/ASGR1, SWEETS).

Latest News

More News

Latest News

Outlook Reports world

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES